PThe Pep Report
Open menu

Peptide
library.

A straightforward reference library for peptides and related compounds: benefits, evidence, practical use, reference dosing and clear context.

Try terms like fat loss, weight loss, recovery, collagen, focus, gut or growth hormone.

Reference ranges shown here are curated educational references, not individualized recommendations. Regulatory status and evidence vary by compound and use.

Human component data · combination unproven

Ipamorelin + CJC no DAC

Commonly marketed growth-hormone-axis combination pairing a short-acting GHRH analogue with the ghrelin-receptor agonist ipamorelin.

Reference

100–300 mcg (3–9 clicks)

2–3× daily on an empty stomach · 8–12 weeks on, 4 weeks off

View peptide →Human topical + preclinical

GHK-Cu

Naturally occurring copper-binding tripeptide researched for collagen signalling, skin quality, extracellular-matrix remodelling and tissue repair.

Reference

1 mg/day (days 1–15), then 2 mg/day

Daily, before bed

View peptide →Component evidence only · blend unvalidated

GLOW

Vendor/community blend name for a co-formulation of GHK-Cu, BPC-157 and TB-500; evidence comes from the individual components rather than the three-peptide blend itself.

Reference

2.5 mg per injection

Daily wk 1–4, 5×/week wk 5–8, 2–3×/week wk 9–12 · 4 weeks off

View peptide →Component evidence only · blend unvalidated

KLOW

Four-peptide research blend combining GHK-Cu, BPC-157, TB-500 and KPV; the evidence base belongs to the individual components rather than the co-formulation.

Reference

1.6–4.8 mg per injection

Daily initially, then 5×/week, then 2–3×/week in the cited 12-week protocol · 12 weeks

View peptide →Cell + animal research · no established human drug data

KPV

Melanocortin-derived tripeptide studied for anti-inflammatory effects in cell and animal models, with no established human drug-exposure data.

Reference

200–500 mcg daily

Daily · 4–8 weeks

View peptide →Small early human studies · unapproved

Melanotan II

Unapproved cyclic melanocortin agonist with small early human studies showing pigmentation and sexual-response effects, alongside significant safety and product-quality concerns.

Reference

50–75 mcg to start, building to 250–500 mcg

Once weekly maintenance · UV exposure after injecting

View peptide →Human endogenous biology + preclinical treatment data

MOTS-c

Naturally occurring 16-amino-acid mitochondrial-derived peptide studied in metabolic stress, exercise and ageing biology, with no established human therapeutic exposure data.

Reference

5–15 mg per week, split into 2–3 injections

2–3× weekly · 2–4 weeks on, 2–4 weeks off

View peptide →Human biochemical data · wellness outcomes unproven

NAD+

Essential cellular redox cofactor and signaling substrate widely marketed for energy and longevity, while direct IV NAD+ wellness outcomes remain insufficiently established.

Reference

25 mg to start, +25 mg every 3 days

3× weekly

View compound →Approved medicine · phase 3 human evidence

PT-141

Bremelanotide is an FDA-approved melanocortin receptor agonist for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

Reference

1.75 mg as needed

As needed · On-demand

View peptide →Phase 3 human trials · investigational

GLP-3 Retatrutide

High-interest investigational triple agonist with substantial human trial evidence across obesity and metabolic research.

Reference

0.5 mg weekly, stepping up by 0.5 mg every 2 weeks to 3 mg

Weekly · 12-week titration, then evaluate

View peptide →Small human anxiety studies · investigational in U.S.

Selank

Tuftsin-derived heptapeptide studied intranasally for anxiety and stress-related effects in small human trials, without FDA approval or a modern large clinical evidence base.

Reference

250–500 mcg

1–2× daily · 2–8 weeks on

View peptide →Limited human intranasal evidence · investigational in U.S.

Semax

ACTH-derived heptapeptide with intranasal human studies in neurologic settings, but limited modern-quality evidence and no FDA-approved U.S. indication.

Reference

300–1,000 mcg

1–3× daily · 2–4 weeks on, 1–2 weeks off

View peptide →FDA accelerated approval · human clinical evidence

SS-31 / Elamipretide

Mitochondrial cardiolipin-binding tetrapeptide now FDA-approved as Forzinity for improving muscle strength in Barth syndrome patients weighing at least 30 kg.

Reference

5–10 mg daily

Daily · 8–12 weeks

View peptide →Approved medicine · randomized human evidence

Tesamorelin

FDA-approved growth-hormone-releasing-factor analogue used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

Reference

1,000–2,000 mcg (16–32 clicks)

Once daily, 5 days/week · 2–3 months on, 1 month off

View peptide →Direct animal combination study · no controlled human blend evidence

BPC-157 / TB-500 (Wolverine)

Research blend name for BPC-157 + TB-500; one 2026 rat tendon study tested the combination directly, but no controlled human blend trial has established efficacy or dosing.

Reference

500 mcg

Daily, morning · 8 weeks on, 8 weeks off

View peptide →Mostly preclinical · very limited human data

BPC-157

Synthetic 15-amino-acid peptide with extensive animal research in tissue-repair and gastrointestinal models but very limited human evidence.

Reference

250–500 mcg daily

Daily · 4–6 weeks

View peptide →Preclinical · no established human exposure data

TB-500

Synthetic thymosin-beta-4-related fragment researched for wound and tissue-repair biology, with no established human clinical evidence for the fragment itself.

Reference

1–2.5 mg

2–3× weekly · 4–6 weeks

View peptide →Approved medicine · extensive human evidence

Semaglutide

GLP-1 receptor agonist with approved prescription products and extensive randomized human evidence across diabetes, obesity and cardiovascular-risk reduction.

Reference

0.25 mg weekly start; maintenance 0.5–2.4 mg weekly, up to 7.2 mg for certain adults

Once-weekly injection; approved oral formulations are taken once daily

View peptide →